Literature DB >> 21697814

TWEAK, a multifunctional cytokine in kidney injury.

Ana Belen Sanz1, Maria D Sanchez-Niño, Alberto Ortiz.   

Abstract

Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a cytokine of the TNF superfamily that activates the Fn14 receptor. TWEAK may regulate cell proliferation, cell death, cell differentiation, and inflammation. TWEAK and Fn14 are constitutively present in the kidney. Sources of TWEAK and Fn14 include intrinsic renal cells and infiltrating leukocytes. Basal Fn14 expression is low, but Fn14 is greatly upregulated during kidney injury. TWEAK contributes to kidney inflammation promoting chemokine secretion by renal cells through canonical and non-canonical NFκB activation. TWEAK also promotes tubular cell proliferation. However, TWEAK induces mesangial and tubular cell apoptosis under proinflammatory conditions. These data indicate that TWEAK is a multifunctional cytokine in the kidney, the actions of which are modulated by the cell microenvironment. Confirmation of the role of TWEAK in kidney injury came from functional studies in experimental animal models. The TWEAK/Fn14 pathway contributed to cell death and interstitial inflammation during acute kidney injury, to glomerular injury in lupus nephritis, to hyperlipidemia-associated kidney injury, and to tubular cell hyperplasia following unilateral nephrectomy. Circulating soluble TWEAK (sTWEAK) levels are a potential biomarker of adverse outcomes in chronic kidney disease and urinary sTWEAK is a potential biomarker of lupus nephritis activity. The available evidence suggests that TWEAK may provide diagnostic information and be a therapeutic target in renal injury. Its role in human kidney disease should be further explored.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21697814     DOI: 10.1038/ki.2011.180

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  40 in total

1.  Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury.

Authors:  Andreas Linkermann; Jan Hinrich Bräsen; Maurice Darding; Mi Kyung Jin; Ana B Sanz; Jan-Ole Heller; Federica De Zen; Ricardo Weinlich; Alberto Ortiz; Henning Walczak; Joel M Weinberg; Douglas R Green; Ulrich Kunzendorf; Stefan Krautwald
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

2.  TWEAK/Fn14 pathway is a novel mediator of retinal neovascularization.

Authors:  Hossein Ameri; Hua Liu; Rong Liu; Yonju Ha; Adriana A Paulucci-Holthauzen; Shuqun Hu; Massoud Motamedi; Bernard F Godley; Ronald G Tilton; Wenbo Zhang
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-10       Impact factor: 4.799

Review 3.  Lupus nephritis: the evolving role of novel therapeutics.

Authors:  Brad H Rovin; Samir V Parikh
Journal:  Am J Kidney Dis       Date:  2014-01-07       Impact factor: 8.860

4.  TWEAK-Fn14 Influences Neurogenesis Status via Modulating NF-κB in Mice with Spinal Cord Injury.

Authors:  Jing Xu; Jian He; Huang He; Renjun Peng; Jian Xi
Journal:  Mol Neurobiol       Date:  2016-11-07       Impact factor: 5.590

5.  Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney disease.

Authors:  Xiaoying Chen; Vahid Farrokhi; Pratap Singh; Mireia Fernandez Ocana; Jenil Patel; Lih-Ling Lin; Hendrik Neubert; Joanne Brodfuehrer
Journal:  MAbs       Date:  2017-11-30       Impact factor: 5.857

6.  The RIP1-kinase inhibitor necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice.

Authors:  Andreas Linkermann; Jan-Ole Heller; Agnes Prókai; Joel M Weinberg; Federica De Zen; Nina Himmerkus; Attila J Szabó; Jan H Bräsen; Ulrich Kunzendorf; Stefan Krautwald
Journal:  J Am Soc Nephrol       Date:  2013-07-05       Impact factor: 10.121

7.  Mitogen-Activated Protein Kinase 14 Promotes AKI.

Authors:  Alberto Ortiz; Holger Husi; Laura Gonzalez-Lafuente; Lara Valiño-Rivas; Manuel Fresno; Ana Belen Sanz; William Mullen; Amaya Albalat; Sergio Mezzano; Tonia Vlahou; Harald Mischak; Maria Dolores Sanchez-Niño
Journal:  J Am Soc Nephrol       Date:  2016-09-12       Impact factor: 10.121

Review 8.  Role of the TWEAK/Fn14 pathway in autoimmune diseases.

Authors:  Wang-Dong Xu; Yi Zhao; Yi Liu
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

Review 9.  Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled.

Authors:  Usama Elewa; Maria Dolores Sanchez-Niño; Catalina Martin-Cleary; Beatriz Fernandez-Fernandez; Jesus Egido; Alberto Ortiz
Journal:  Int Urol Nephrol       Date:  2012-09-11       Impact factor: 2.370

Review 10.  A further TWEAK to multiple sclerosis pathophysiology.

Authors:  Arash Nazeri; Pouria Heydarpour; Shokufeh Sadaghiani; Mohammad Ali Sahraian; Linda C Burkly; Amit Bar-Or
Journal:  Mol Neurobiol       Date:  2013-07-20       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.